Literature DB >> 28578651

Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells.

Laleh Sharifi1, Monireh Mohsenzadegan2, Asghar Aghamohammadi1,3, Nima Rezaei1,4,5, Farzaneh Tofighi Zavareh1,6, Saied Bokaie7, Mona Moshiri8, Zahra Aghazadeh6, Zahra Norouzbabaie9, Gholamreza Azizi10, Abbas Mirshafiey11,6.   

Abstract

BACKGROUND: Inhibition of Toll-like receptors (TLRs) signaling has been established as a new method for the development of anti-inflammatory drugs instead of NSAIDs (non-steroid anti-inflammatory drugs). Since the immunomodulatory role of G2013 (α-L-Guluronic acid) was reported in some recent experiments, we decided to assess the effects of G2013 on the protein expression of TLR2 and TLR4, their downstream signaling cascade, and the secretion of pro-inflammatory cytokines in human peripheral blood mononuclear cells (PBMCs).
METHODS: After blood sampling from 16 healthy donors, PBMCs were isolated and treated with/without lipopolysaccharide (LPS), lipopolyteichoic acid (LTA), and G2013. Flow cytometry was done for detecting the protein expression of TLR2 and TLR4. MyD88, IκB, Tollip, and NF-κB mRNA expression were assessed by realtime PCR. ELISA was performed for assessing the concentration of IL-1β and IL-6.
RESULTS: G2013 at a concentration of 25 µg/mL (high dose) significantly downregulated NF-κB, IκB and MyD88 mRNA expression and suppressed the secretion of IL-1β by PBMCs. The findings indicate that G2013 may exert its regulatory effect under normal condition via Tollip in a dose dependence pathway. Our results demonstrated that G2013 had no profound impact on the protein expression of TLR2 and TLR4.
CONCLUSION: In conclusion, our findings point to the immunomodulatory effect of G2013 on the TLR2 and TLR4 signaling cascade and cytokine production by PBMCs. These findings could lead to an establishment of new safe anti-inflammatory drugs in the future. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  G2013; Guluronic acid; IL-1; IL-6; IκB; MyD88; NF-κB; TLR2; TLR4; Tollip.

Mesh:

Substances:

Year:  2018        PMID: 28578651     DOI: 10.2174/1570163814666170605111331

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  5 in total

1.  Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.

Authors:  Seyed Shahabeddin Mortazavi-Jahromi; Sepideh Nazeri; Fahimeh Jafarnezhad-Ansariha; Mona Oraei; Abbas Mirshafiey
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.

Authors:  Elham Kalantari; Maryam Abolhasani; Raheleh Roudi; Mohammad M Farajollahi; Seif Farhad; Zahra Madjd; Shaghayegh Askarian-Amiri; Monireh Mohsenzadegan
Journal:  Int J Exp Pathol       Date:  2019-05-14       Impact factor: 1.925

Review 3.  Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.

Authors:  Ian F Caplan; Kathleen A Maguire-Zeiss
Journal:  Front Pharmacol       Date:  2018-05-04       Impact factor: 5.810

4.  The Inhibitory Role of M2000 (β-D-Mannuronic Acid) on Expression of Toll-like Receptor 2 and 4 in HT29 Cell Line.

Authors:  Laleh Sharifi; Mona Moshiri; Mohammad M S Dallal; Mohammad H Asgardoon; Maryam Nourizadeh; Saied Bokaie; Abbas Mirshafiey
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

5.  Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis.

Authors:  Xu Zhang; Ting Li; Xi Chen; Suxia Wang; Zhaohui Liu
Journal:  BMC Microbiol       Date:  2018-10-25       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.